Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
E1
- Development stage
- Preclinical
- Lead developer
- Profluent Bio
- Modality
- CRISPR-Cas9 → CRISPR Systems → Programmable Nucleases → Gene Editing → Gene Therapies, Recombinant Proteins and Enzymes
01
Overview
E1 is an AI-generated CRISPR effector developed by Profluent Bio. It was designed using the company's proprietary AI foundation models, which are trained on vast genomic and proteomic datasets to create novel proteins from scratch. E1 is a Cas9-like nuclease that has been optimized for high editing efficiency and specificity, aiming to overcome the limitations of naturally occurring CRISPR enzymes. Profluent released a version of this technology, known as OpenCRISPR-1, as an open-source tool to facilitate the development of next-generation gene therapies. While E1 is a component of Profluent's broader protein design platform, it represents a specific, functional gene-editing tool intended for therapeutic applications in human health, as well as uses in agriculture and industry.
- Other names
- OpenCRISPR-1OpenCRISPR1OpenCRISPR 1
02
Targets
DNA
Beyond the preview
Go deeper on E1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on E1.